New drug shows promise for tough stomach cancer

NCT ID NCT06123468

Completed Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 15 times

Summary

This study tested a drug called sacituzumab-govitecan in 58 people with advanced stomach cancer that had spread. The drug targets a protein on cancer cells to deliver chemotherapy directly. The goal was to see if it could shrink tumors or slow the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hämatologisch-Onkologische Praxis Eppendorf

Hamburg, 20249, Germany
Klinikum rechts der Isar der TU München

München, 81675, Germany
Nationales Centrum für Tumorerkrankungen

Heidelberg, 69120, Germany
Onkopraxis Probstheida

Leipzig, 04289, Germany
SCRI-CCCIT GmbH

Salzburg, 5020, Austria
Universitätsklinikum Jena

Jena, 07747, Germany
Universitätsklinikum Leipzig

Leipzig, 04103, Germany
Universitätsklinikum Mannheim

Mannheim, 68167, Germany

Conditions

Explore the condition pages connected to this study.

ESOPHAGOGASTRIC ADENOCARCINOMA